OSLO, Norway--(BUSINESS WIRE)--DiaGenic ASA today announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is funding a DiaGenic study with Dr. Clemens R. Scherzer, Assistant Professor of Neurology at Brigham and Women’s Hospital and Harvard Medical School, to develop the first blood test for Parkinson’s disease: a gene expression signature for the early detection of PD. This involves the identification and independent validation of a unique gene expression signature for Parkinson’s using peripheral blood. Over the last three years, Dr. Scherzer and colleagues have established the Harvard PD Biomarker Study, funded by MJFF, a unique study designed for discovery and validation of blood tests for Parkinson’s disease. Since blood samples have already been collected, we can immediately start on the analytical and bioinformatics studies. This will ensure the rapid development of a prototype blood test followed by an approved diagnostic test for early detection of Parkinson’s disease.
